Business context and reporting period
Important entity mismatch: The supplied filing is Edge Therapeutics, Inc.’s Form 10-K for the fiscal year ended December 31, 2018, filed February 21, 2019—not a PDS Biotechnology Corp. 10-K. The period is full-year 2018, not a standalone fourth quarter.
Edge was a clinical-stage biotechnology company. After its Phase 3 NEWTON 2 study of EG-1962 was discontinued, Edge stopped research and development on its product candidates, reduced its workforce, and pursued strategic alternatives. On November 23, 2018, Edge agreed to merge with privately held PDS Biotechnology; completion remained subject to closing conditions. If completed, the combined company was expected to focus on PDS’s cancer immunotherapy pipeline.
Financial and operating metrics
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $16.1 million | $34.3 million |
| General and administrative expense | $14.3 million | $17.7 million |
| Restructuring expense | $9.9 million | None reported |
| Impairment charge | $2.8 million | None reported |
| Net loss | $40.9 million | $50.9 million |
| Net loss per share | $1.31 | $1.67 |
| Operating cash used | $33.2 million | $40.7 million |
| Cash and cash equivalents at year-end | $34.6 million | $88.1 million |
| Debt at year-end | None | $20.5 million |
Total operating expenses were $43.1 million versus $52.0 million in 2017. No revenue was reported, so revenue margins are not meaningful. Current assets were $35.7 million and current liabilities $6.4 million at year-end. Cash declined by $53.4 million, including $20.0 million of debt principal repayment and $1.0 million of back-end fees. Stockholders’ equity was $29.8 million; accumulated deficit was $192.8 million.
Material changes versus the prior comparable period
- R&D expense fell 53%, primarily because clinical work ended and the workforce was reduced.
- G&A expense declined 19%. Total operating expenses fell 17%, while net loss narrowed 20%.
- 2018 included $9.9 million of restructuring costs (severance, advisory, legal and retention expenses) and a $2.8 million write-down of EG-1962-related equipment.
- Operating cash use decreased by $7.5 million, but year-end cash fell substantially, principally due to operating burn and repayment of the Hercules loan.
- The Hercules debt was repaid in full in June 2018; no debt remained at December 31, 2018.
Outlook, risks, contingencies and unusual items
- Management said year-end cash was expected to fund anticipated requirements for at least 12 months. This estimate depends on assumptions and the timing and costs of the PDS merger, litigation, restructuring, and any alternative strategy.
- The merger was central to Edge’s future. If it failed, Edge said it could seek another strategic transaction or dissolve and liquidate; any shareholder distribution would depend on obligations, reserves and remaining cash.
- NEWTON 2 was stopped after interim analysis indicated a low probability of meeting its primary endpoint. Final overall Day 90 favorable outcomes were 46% for EG-1962 and 43% for nimodipine; the severe-subgroup comparison was 46% versus 32% and was not statistically significant. No EG-1962 safety concern was identified by the DMC.
- Merger-related risks included a possible $1.75 million termination fee, estimated transaction costs of approximately $5.3 million (about $3.5 million payable even if the merger failed), dilution, reverse-stock-split and Nasdaq initial-listing requirements, and the possibility of additional capital needs.
- Nasdaq had notified Edge of noncompliance with audit committee and bid-price requirements. The combined company would need to meet Nasdaq initial listing standards.
- A securities class action relating to EG-1962 was voluntarily dismissed without prejudice in February 2019. Four merger-disclosure lawsuits were pending in their initial stages; Edge said it believed them without merit.
- Edge reported federal NOL carryforwards of approximately $101.5 million plus $27.1 million generated in 2018, but said use may be limited under Section 382, including following the merger. Deferred tax assets were fully offset by a valuation allowance.
- Management reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an internal-control effectiveness opinion.
Most important facts for investors to verify
- Confirm the intended issuer and filing: this is Edge Therapeutics’ 2018 Form 10-K, not a PDS Biotechnology filing.
- Check the merger’s ultimate closing status, final exchange ratio, reverse-split terms, and combined-company Nasdaq listing outcome.
- Verify subsequent cash burn, transaction and wind-down costs, and whether the stated 12-month liquidity expectation held.
- Review the status and potential financial exposure of merger-related litigation and any remaining restructuring or contractual obligations.
- Assess any later clinical results and development plans for PDS’s programs; the filing’s PDS pipeline descriptions are forward-looking, not evidence of efficacy or commercial success.